Cargando…

Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging: Multi-Center Prospective Regenerative Aesthetic Medicine Study Using Exokine®

BACKGROUND: The “Inflammation Theory of Ageing” identifies pro-inflammatory cytokines and oxidative damage as one cause of cellular and mitochondrial deterioration and aging. Cell-free blood cell secretome (BCS) also known as autologous conditioned serum (ACS) has shown anti-inflammatory and regener...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerscher, Martina, Wagner-Schiffler, Sylvia, Noah, Ernst Magnus, Fischer, Tanja, Greiner-Krüger, Daniela, Sattler, Sonja, Kaptan, Tanju, Drabik, Attyla, Hamed, Glyn, Reinecke, Julio, Wehling, Jana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248816/
https://www.ncbi.nlm.nih.gov/pubmed/35784268
http://dx.doi.org/10.2147/CCID.S357810
_version_ 1784739440672899072
author Kerscher, Martina
Wagner-Schiffler, Sylvia
Noah, Ernst Magnus
Fischer, Tanja
Greiner-Krüger, Daniela
Sattler, Sonja
Kaptan, Tanju
Drabik, Attyla
Hamed, Glyn
Reinecke, Julio
Wehling, Jana
author_facet Kerscher, Martina
Wagner-Schiffler, Sylvia
Noah, Ernst Magnus
Fischer, Tanja
Greiner-Krüger, Daniela
Sattler, Sonja
Kaptan, Tanju
Drabik, Attyla
Hamed, Glyn
Reinecke, Julio
Wehling, Jana
author_sort Kerscher, Martina
collection PubMed
description BACKGROUND: The “Inflammation Theory of Ageing” identifies pro-inflammatory cytokines and oxidative damage as one cause of cellular and mitochondrial deterioration and aging. Cell-free blood cell secretome (BCS) also known as autologous conditioned serum (ACS) has shown anti-inflammatory and regenerative mode of action in musculoskeletal disorders and radicular compression. AIM: To confirm that BCS can improve signs of skin aging from a previous study in a multi-center setting. METHODS: Prospective, one-armed, multi-center interventional therapeutic study. Ninety-five women with skin firmness loss were treated with four intra-dermal injection sessions in both cheeks at 0, 2, 4 and 6 weeks. BCS was processed with Exokine® medical device according to manufacturer’s instructions. Primary endpoints were cutometric R0 and R3 at 12 and 24 weeks. GAIS, FACE-Q(TM), Patient Attractivity Self-Assessment and safety were evaluated. RESULTS: Mean skin firmness (R0) improved significantly from baseline 0.40 mm to 0.38 mm at week 12 and to 0.36 mm at week 24. Mean skin tiring (R3) improved significantly from baseline 0.45 mm to 0.42 mm at week 12 and to 0.40 at week 24. FACE-Q(TM) “Satisfaction with Skin” significantly improved from baseline to weeks 12, 24 and 48. So did “Satisfaction with Facial Appearance” and “Psychological and Social Function”. “Satisfaction with Decision” and “Satisfaction with Outcome” were stable at week 24 and 48. At week 48 patients assessed their age 1.68 years younger vs Baseline. FACE-Q(TM) aging appraisal improves from Baseline 52.94 to 65.23 at week 48. GAIS, by both physicians and patients, confirm improvement of skin. CONCLUSION: For up to 48 weeks four intra-dermal injections with cell-free BCS increase facial skin firmness and resilience to tiring and patients’ satisfaction with their facial appearance and skin. Patients perceive their face as younger. BCS has the ability to sustainably rejuvenate facial skin safely. STUDY REGISTRATION: Registration on German clinical trials register: DRKS00013014.
format Online
Article
Text
id pubmed-9248816
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92488162022-07-02 Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging: Multi-Center Prospective Regenerative Aesthetic Medicine Study Using Exokine® Kerscher, Martina Wagner-Schiffler, Sylvia Noah, Ernst Magnus Fischer, Tanja Greiner-Krüger, Daniela Sattler, Sonja Kaptan, Tanju Drabik, Attyla Hamed, Glyn Reinecke, Julio Wehling, Jana Clin Cosmet Investig Dermatol Clinical Trial Report BACKGROUND: The “Inflammation Theory of Ageing” identifies pro-inflammatory cytokines and oxidative damage as one cause of cellular and mitochondrial deterioration and aging. Cell-free blood cell secretome (BCS) also known as autologous conditioned serum (ACS) has shown anti-inflammatory and regenerative mode of action in musculoskeletal disorders and radicular compression. AIM: To confirm that BCS can improve signs of skin aging from a previous study in a multi-center setting. METHODS: Prospective, one-armed, multi-center interventional therapeutic study. Ninety-five women with skin firmness loss were treated with four intra-dermal injection sessions in both cheeks at 0, 2, 4 and 6 weeks. BCS was processed with Exokine® medical device according to manufacturer’s instructions. Primary endpoints were cutometric R0 and R3 at 12 and 24 weeks. GAIS, FACE-Q(TM), Patient Attractivity Self-Assessment and safety were evaluated. RESULTS: Mean skin firmness (R0) improved significantly from baseline 0.40 mm to 0.38 mm at week 12 and to 0.36 mm at week 24. Mean skin tiring (R3) improved significantly from baseline 0.45 mm to 0.42 mm at week 12 and to 0.40 at week 24. FACE-Q(TM) “Satisfaction with Skin” significantly improved from baseline to weeks 12, 24 and 48. So did “Satisfaction with Facial Appearance” and “Psychological and Social Function”. “Satisfaction with Decision” and “Satisfaction with Outcome” were stable at week 24 and 48. At week 48 patients assessed their age 1.68 years younger vs Baseline. FACE-Q(TM) aging appraisal improves from Baseline 52.94 to 65.23 at week 48. GAIS, by both physicians and patients, confirm improvement of skin. CONCLUSION: For up to 48 weeks four intra-dermal injections with cell-free BCS increase facial skin firmness and resilience to tiring and patients’ satisfaction with their facial appearance and skin. Patients perceive their face as younger. BCS has the ability to sustainably rejuvenate facial skin safely. STUDY REGISTRATION: Registration on German clinical trials register: DRKS00013014. Dove 2022-06-27 /pmc/articles/PMC9248816/ /pubmed/35784268 http://dx.doi.org/10.2147/CCID.S357810 Text en © 2022 Kerscher et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Kerscher, Martina
Wagner-Schiffler, Sylvia
Noah, Ernst Magnus
Fischer, Tanja
Greiner-Krüger, Daniela
Sattler, Sonja
Kaptan, Tanju
Drabik, Attyla
Hamed, Glyn
Reinecke, Julio
Wehling, Jana
Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging: Multi-Center Prospective Regenerative Aesthetic Medicine Study Using Exokine®
title Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging: Multi-Center Prospective Regenerative Aesthetic Medicine Study Using Exokine®
title_full Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging: Multi-Center Prospective Regenerative Aesthetic Medicine Study Using Exokine®
title_fullStr Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging: Multi-Center Prospective Regenerative Aesthetic Medicine Study Using Exokine®
title_full_unstemmed Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging: Multi-Center Prospective Regenerative Aesthetic Medicine Study Using Exokine®
title_short Cell-Free Blood Cell Secretome (BCS) Counteracts Skin Aging: Multi-Center Prospective Regenerative Aesthetic Medicine Study Using Exokine®
title_sort cell-free blood cell secretome (bcs) counteracts skin aging: multi-center prospective regenerative aesthetic medicine study using exokine®
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248816/
https://www.ncbi.nlm.nih.gov/pubmed/35784268
http://dx.doi.org/10.2147/CCID.S357810
work_keys_str_mv AT kerschermartina cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT wagnerschifflersylvia cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT noahernstmagnus cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT fischertanja cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT greinerkrugerdaniela cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT sattlersonja cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT kaptantanju cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT drabikattyla cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT hamedglyn cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT reineckejulio cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine
AT wehlingjana cellfreebloodcellsecretomebcscounteractsskinagingmulticenterprospectiveregenerativeaestheticmedicinestudyusingexokine